{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:36:58Z","timestamp":1695274618094},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Glomerul\u00e4re Erkrankungen sind mit extrarenalen Komplikationen vergesellschaftet, etwa mit thromboembolischen Ereignissen, einem erh\u00f6hten kardiovaskul\u00e4ren Risiko und insbesondere einer deutlich erh\u00f6hten Neigung zu Infektionen. Daher ist eine genaue Kenntnis der verschiedenen Immunsuppressiva und ihrer typischen Nebenwirkungsprofile von gro\u00dfer Bedeutung. W\u00e4hrend Nephrolog:innen mit Calcineurin-Inhibitoren und Antimetaboliten \u00fcblicherweise aus der Transplantationsmedizin viel Erfahrung aufweisen, kommen zwei f\u00fcr die Therapie immunmediierter Nierenerkrankungen relevante Wirkstoffe (Rituximab, in schwerwiegenden F\u00e4llen auch Cyclophosphamid) vergleichsweise selten zur Anwendung und werden hier vertiefend besprochen. Au\u00dferdem werden praxisgerechte Empfehlungen zur Thromboseprophylaxe beim nephrotischen Syndrom sowie zur Vorbeugung einer wichtigen opportunistischen Infektion, der Pneumocystis jirovecii Pneumonie, gegeben.<\/jats:p>","DOI":"10.1007\/s00508-023-02265-6","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:01:56Z","timestamp":1695214916000},"page":"696-704","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allgemeine Empfehlungen f\u00fcr die Behandlung glomerul\u00e4rer Erkrankungen\u00a0\u2013 2023","General recommendations for the management of glomerular diseases\u20142023"],"prefix":"10.1007","volume":"135","author":[{"given":"Martin","family":"Windpessl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Lhotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmgard","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"2265_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad080","author":"M Windpessl","year":"2023","unstructured":"Windpessl M, Kostopoulou M, Conway R, Mentese IB, Bruchfeld A, Soler MJ, et\u00a0al. Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis. Nephrol Dial Transplant. 2023. https:\/\/doi.org\/10.1093\/ndt\/gfad080.","journal-title":"Nephrol Dial Transplant"},{"key":"2265_CR2","unstructured":"https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Impfen\/Impfplan-%C3%96sterreich.html. Zugegriffen: 27.07.2023."},{"key":"2265_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00393-021-01028-w","volume":"80","author":"J Leipe","year":"2021","unstructured":"Leipe\u00a0J, Holle\u00a0JU, Weseloh\u00a0C, Pfeil\u00a0A, Kr\u00fcger\u00a0K. Empfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose. Z\u00a0Rheumatol. 2021;80:670\u201387.","journal-title":"Z Rheumatol"},{"key":"2265_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull\u00a0RP, Goldsmith\u00a0DJ. Nephrotic syndrome in adults. BMJ. 2008;336:1185\u20139.","journal-title":"BMJ"},{"key":"2265_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin\u00a0BA, Ayoob\u00a0R, Smoyer\u00a0WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7:513\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2265_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","volume":"117","author":"BK Mahmoodi","year":"2008","unstructured":"Mahmoodi\u00a0BK, ten Kate\u00a0MK, Waanders\u00a0F, Veeger\u00a0NJ, Brouwer\u00a0JL, Vogt\u00a0L, et\u00a0al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a\u00a0large retrospective cohort study. Circulation. 2008;117:224\u201330.","journal-title":"Circulation"},{"key":"2265_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.kint.2022.01.010","volume":"101","author":"X Gao","year":"2022","unstructured":"Gao\u00a0X, Liu\u00a0Y, He\u00a0Q, Shen\u00a0X. Cerebral venous sinus thrombosis in nephrotic syndrome. Kidney Int. 2022;101:1303.","journal-title":"Kidney Int"},{"key":"2265_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.krcp.2014.07.001","volume":"33","author":"BS Park","year":"2014","unstructured":"Park\u00a0BS, Park\u00a0S, Jin\u00a0K, Choi\u00a0G, Park\u00a0KM, Jo\u00a0KM, et\u00a0al. Nephrotic syndrome complicated with portal, splenic, and superior mesenteric vein thrombosis. Kidney Res Clin Pract. 2014;33:161\u20134.","journal-title":"Kidney Res Clin Pract"},{"key":"2265_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir\u00a0SA, Horv\u00e1th-Puh\u00f3\u00a0E, Dekkers\u00a0OM, Cannegieter\u00a0SC, J\u00f8rgensen\u00a0JO, Ehrenstein\u00a0V, et al. Use of glucocorticoids and risk of venous thromboembolism: a\u00a0nationwide population-based case-control study. JAMA Intern Med. 2013;173:743\u201352.","journal-title":"JAMA Intern Med"},{"key":"2265_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000448628","volume":"135","author":"AJ Rankin","year":"2017","unstructured":"Rankin\u00a0AJ, McQuarrie\u00a0EP, Fox\u00a0JG, Geddes\u00a0CC, MacKinnon\u00a0B. Scottish renal biopsy registry. Venous thromboembolism in primary nephrotic syndrome\u2014is the risk high enough to justify prophylactic anticoagulation? Nephron. 2017;135:39\u201345.","journal-title":"Nephron"},{"key":"2265_CR11","first-page":"355","volume":"49","author":"V Garcia Moreira","year":"2018","unstructured":"Garcia Moreira\u00a0V, Beridze Vaktangova\u00a0N, Martinez Gago\u00a0MD, Laborda Gonzalez\u00a0B, Garcia Alonso\u00a0S, Fernandez Rodriguez\u00a0E. Overestimation of albumin measured by bromocresol green vs bromocresol purple method: influence of acute-phase globulins. Lab Med. 2018;49:355\u201361.","journal-title":"Lab Med"},{"issue":"4S","key":"2265_CR12","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013S276.","journal-title":"Kidney Int"},{"key":"2265_CR13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/ki.2013.476","volume":"85","author":"T Lee","year":"2014","unstructured":"Lee\u00a0T, Biddle\u00a0AK, Lionaki\u00a0S, Derebail\u00a0VK, Barbour\u00a0SJ, Tannous\u00a0S, et\u00a0al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 2014;85:1412\u201320.","journal-title":"Kidney Int"},{"key":"2265_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1159\/000345475","volume":"36","author":"DJ Sexton","year":"2012","unstructured":"Sexton\u00a0DJ, Clarkson\u00a0MR, Mazur\u00a0MJ, Plant\u00a0WD, Eustace\u00a0JA. Serum D\u2011dimer concentrations in nephrotic syndrome track with albuminuria, not estimated glomerular filtration rate. Am J Nephrol. 2012;36:554\u201360.","journal-title":"Am J Nephrol"},{"key":"2265_CR15","first-page":"75","volume":"25","author":"D Ganeval","year":"1986","unstructured":"Ganeval\u00a0D, Fischer\u00a0AM, Barre\u00a0J, Pertuiset\u00a0N, Dautzenberg\u00a0MD, Jungers\u00a0P, et al. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K\u2011dependent clotting factors. Clin Nephrol. 1986;25:75\u201380.","journal-title":"Clin Nephrol"},{"key":"2265_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","volume":"97","author":"VK Derebail","year":"2020","unstructured":"Derebail\u00a0VK, Rheault\u00a0MN, Kerlin\u00a0BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97:664\u201375.","journal-title":"Kidney Int"},{"key":"2265_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2215\/CJN.07190713","volume":"9","author":"N Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas\u00a0N, Ziaj\u00a0S, Condon\u00a0M, Galliford\u00a0J, Levy\u00a0J, Cairns\u00a0T, Griffith\u00a0M. Retrospective analysis of a\u00a0novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol. 2014;9:478\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2265_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000188355","volume":"69","author":"G Rostoker","year":"1995","unstructured":"Rostoker\u00a0G, Durand-Zaleski\u00a0I, Petit-Phar\u00a0M, Ben Maadi\u00a0A, Jazaerli\u00a0N, Radier\u00a0C, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron. 1995;69:20\u20138.","journal-title":"Nephron"},{"key":"2265_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.kint.2016.01.019","volume":"89","author":"JM Hofstra","year":"2016","unstructured":"Hofstra\u00a0JM, Wetzels\u00a0JFM. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? Kidney Int. 2016;89:981\u20133.","journal-title":"Kidney Int"},{"key":"2265_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH, Berti\u00a0A, Blockmans\u00a0D, Cid\u00a0MC, Holle\u00a0JU, Hollinger\u00a0N, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023; https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"2265_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park\u00a0JW, Curtis\u00a0JR, Moon\u00a0J, Song\u00a0YW, Kim\u00a0S, Lee\u00a0EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77:644\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2265_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler\u00a0A, Kerschbaum\u00a0J, Gopaluni\u00a0S, Tieu\u00a0J, Alberici\u00a0F, Jones\u00a0RB, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77:1440\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2265_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/03009742.2021.2001929","volume":"52","author":"M G\u00e9rard","year":"2023","unstructured":"G\u00e9rard\u00a0M, de Boysson\u00a0H, Morello\u00a0R, Martin-Silva\u00a0N, Leroux\u00a0AC, Dumont\u00a0A, et al. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy. Scand J Rheumatol. 2023;52:161\u201373.","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 129","key":"2265_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.55563\/clinexprheumatol\/p34lkr","volume":"39","author":"D Waki","year":"2021","unstructured":"Waki\u00a0D, Nishimura\u00a0K, Yoshida\u00a0T, Tanaka\u00a0N, Mizukawa\u00a0K, Fukushima\u00a0M, et al. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Clin Exp Rheumatol. 2021;39(Suppl 129):142\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler\u00a0B, Riedl\u00a0R, Gauckler\u00a0P, Shin\u00a0JI, Leierer\u00a0J, Merkel\u00a0PA, et al. RAVE\u2212ITN Research Group. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023;82(5):681\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2265_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/cid\/ciab474","volume":"74","author":"MM Azar","year":"2022","unstructured":"Azar\u00a0MM, Cohen\u00a0E, Ma\u00a0L, Ciss\u00e9\u00a0OH, Gan\u00a0G, Deng\u00a0Y, et\u00a0al. Genetic and epidemiologic analyses of an outbreak of pneumocystis jirovecii pneumonia among kidney transplant recipients in the United States. Clin Infect Dis. 2022;74:639\u201347.","journal-title":"Clin Infect Dis"},{"key":"2265_CR27","doi-asserted-by":"publisher","first-page":"152154","DOI":"10.1016\/j.semarthrit.2022.152154","volume":"58","author":"N Anumolu","year":"2023","unstructured":"Anumolu\u00a0N, Henry\u00a0K, Sattui\u00a0SE, Putman\u00a0M. Is there a\u00a0role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica? Semin Arthritis Rheum. 2023;58:152154.","journal-title":"Semin Arthritis Rheum"},{"key":"2265_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park\u00a0JW, Curtis\u00a0JR, Jun\u00a0KI, Kim\u00a0TM, Heo\u00a0DS, Ha\u00a0J, et\u00a0al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving Rituximab. Chest. 2022;161:1201\u201310.","journal-title":"Chest"},{"key":"2265_CR29","doi-asserted-by":"publisher","first-page":"152106","DOI":"10.1016\/j.semarthrit.2022.152106","volume":"57","author":"B Boone","year":"2022","unstructured":"Boone\u00a0B, Lazaroff\u00a0SM, Wheless\u00a0L, Wolfe\u00a0RM, Barnado\u00a0A. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a\u00a0large electronic health record cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2022;57:152106.","journal-title":"Semin Arthritis Rheum"},{"key":"2265_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/RHU.0b013e31829d5017","volume":"19","author":"CT Weng","year":"2013","unstructured":"Weng\u00a0CT, Liu\u00a0MF, Weng\u00a0MY, Lee\u00a0NY, Wang\u00a0MC, Lin\u00a0WC, et\u00a0al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J\u00a0Clin Rheumatol. 2013;19:252\u20138.","journal-title":"J Clin Rheumatol"},{"key":"2265_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","volume":"16","author":"A Kronbichler","year":"2017","unstructured":"Kronbichler\u00a0A, Windpessl\u00a0M, Pieringer\u00a0H, Jayne\u00a0DRW. Rituximab for immunologic renal disease: What the nephrologist needs to know. Autoimmun Rev. 2017;16:633\u201343.","journal-title":"Autoimmun Rev"},{"key":"2265_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3109\/03009742.2012.739638","volume":"42","author":"JW Gregersen","year":"2013","unstructured":"Gregersen\u00a0JW, Chaudhry\u00a0A, Jayne\u00a0DR. Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42:207\u201310.","journal-title":"Scand J Rheumatol"},{"key":"2265_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1753495X18780853","volume":"13","author":"A Pefanis","year":"2020","unstructured":"Pefanis\u00a0A, Williams\u00a0DS, Skrzypek\u00a0H, Fung\u00a0A, Paizis\u00a0K. A\u00a0case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab. Obstet Med. 2020;13:41\u20134.","journal-title":"Obstet Med"},{"key":"2265_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen\u00a0C, Hoeltzenbein\u00a0M, Tincani\u00a0A, Fischer-Betz\u00a0R, Elefant\u00a0E, Chambers\u00a0C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"2265_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","volume":"24","author":"T Brummaier","year":"2013","unstructured":"Brummaier\u00a0T, Pohanka\u00a0E, Studnicka-Benke\u00a0A, Pieringer\u00a0H. Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med. 2013;24:590\u20136.","journal-title":"Eur J Intern Med"},{"key":"2265_CR36","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau\u00a0FA, Vasconcelos\u00a0C, D\u2019Cruz\u00a0D, Sebastiani\u00a0GD, Garrido\u00a0E, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a\u00a0randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121\u201331.","journal-title":"Arthritis Rheum"},{"key":"2265_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","volume":"340","author":"DT Boumpas","year":"1992","unstructured":"Boumpas\u00a0DT, Austin\u00a0HA 3rd, Vaughn\u00a0EM, Klippel\u00a0JH, Steinberg\u00a0AD, Yarboro\u00a0CH, et\u00a0al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741\u20135.","journal-title":"Lancet"},{"key":"2265_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones\u00a0RB, Tervaert\u00a0JW, Hauser\u00a0T, Luqmani\u00a0R, Morgan\u00a0MD, Peh\u00a0CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculiti. N\u00a0Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"2265_CR39","first-page":"260","volume":"58","author":"RJ Pepper","year":"2019","unstructured":"Pepper\u00a0RJ, McAdoo\u00a0SP, Moran\u00a0SM, Kelly\u00a0D, Scott\u00a0J, Hamour\u00a0S, et al. A\u00a0novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019;58:260\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"2265_CR40","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot\u00a0K, Harper\u00a0L, Jayne\u00a0DR, Flores Suarez\u00a0LF, Gregorini\u00a0G, Gross\u00a0WL, et al. EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized trial. Ann Intern Med. 2009;150:670\u201380.","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"2265_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00393-017-0393-2","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Moosig\u00a0F. S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z\u00a0Rheumatol. 2017;76(Suppl 3):75\u20136.","journal-title":"Z Rheumatol"},{"key":"2265_CR42","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3899\/jrheum.150065","volume":"42","author":"N Yilmaz","year":"2015","unstructured":"Yilmaz\u00a0N, Emmungil\u00a0H, Gucenmez\u00a0S, Ozen\u00a0G, Yildiz\u00a0F, Balkarli\u00a0A, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J\u00a0Rheumatol. 2015;42:1661\u20136.","journal-title":"J Rheumatol"},{"key":"2265_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2215\/CJN.07300712","volume":"8","author":"R Goupil","year":"2013","unstructured":"Goupil\u00a0R, Brachemi\u00a0S, Nadeau-Fredette\u00a0AC, D\u00e9ziel\u00a0C, Troyanov\u00a0Y, Lavergne\u00a0V, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013;8:416\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2265_CR44","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","volume":"54","author":"M Faurschou","year":"2015","unstructured":"Faurschou\u00a0M, Mellemkjaer\u00a0L, Voss\u00a0A, Keller\u00a0KK, Hansen\u00a0IT, Baslund\u00a0B. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54:1345\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"2265_CR45","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen\u00a0EE, Rizzo\u00a0R, Kronbichler\u00a0A, Wolterbeek\u00a0R, Bruijn\u00a0JA, Jayne\u00a0DR, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02265-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:18:25Z","timestamp":1695215905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02265-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02265-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Windpessl, P.\u00a0Gauckler, E.\u00a0Zitt, K.\u00a0Lhotta, C.\u00a0Ay, K.\u00a0Eller, B.\u00a0Odler, I.\u00a0Neumann, M.\u00a0Rudnicki, A.\u00a0Kronbichler und M.D.\u00a0S\u00e4emann geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}